Navigating Lipodystrophy: Insights from Laminopathies and Beyond.

Krüger, Peter; Hartinger, Ramona; Djabali, Karima

Krüger, Peter; Hartinger, Ramona; Djabali, Karima.

Afiliación

Krüger P; Epigenetics of Aging, Department of Dermatology and Allergy, TUM School of Medicine, Munich Institute of Biomedical Engineering (MIBE), Technical University of Munich (TUM), 85748 Garching, Germany.
Hartinger R; Epigenetics of Aging, Department of Dermatology and Allergy, TUM School of Medicine, Munich Institute of Biomedical Engineering (MIBE), Technical University of Munich (TUM), 85748 Garching, Germany.
Djabali K; Epigenetics of Aging, Department of Dermatology and Allergy, TUM School of Medicine, Munich Institute of Biomedical Engineering (MIBE), Technical University of Munich (TUM), 85748 Garching, Germany.

Int J Mol Sci ; 25(15)2024 Jul 23.

Article en En | MEDLINE | ID: mdl-39125589

ABSTRACT

ABSTRACT

Recent research into laminopathic lipodystrophies-rare genetic disorders caused by mutations in the LMNA gene-has greatly expanded our knowledge of their complex pathology and metabolic implications. These disorders, including Hutchinson-Gilford progeria syndrome (HGPS), Mandibuloacral Dysplasia (MAD), and Familial Partial Lipodystrophy (FPLD), serve as crucial models for studying accelerated aging and metabolic dysfunction, enhancing our understanding of the cellular and molecular mechanisms involved. Research on laminopathies has highlighted how LMNA mutations disrupt adipose tissue function and metabolic regulation, leading to altered fat distribution and metabolic pathway dysfunctions. Such insights improve our understanding of the pathophysiological interactions between genetic anomalies and metabolic processes. This review merges current knowledge on the phenotypic classifications of these diseases and their associated metabolic complications, such as insulin resistance, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome, all of which elevate the risk of cardiovascular disease, stroke, and diabetes. Additionally, a range of published therapeutic strategies, including gene editing, antisense oligonucleotides, and novel pharmacological interventions aimed at addressing defective adipocyte differentiation and lipid metabolism, will be explored. These therapies target the core dysfunctional lamin A protein, aiming to mitigate symptoms and provide a foundation for addressing similar metabolic and genetic disorders.

Asunto(s)

Lamina Tipo A; Lipodistrofia; Humanos; Lamina Tipo A/genética; Lamina Tipo A/metabolismo; Lipodistrofia/genética; Lipodistrofia/metabolismo; Lipodistrofia/terapia; Animales; Laminopatías/genética; Laminopatías/metabolismo; Progeria/genética; Progeria/metabolismo; Progeria/patología; Mutación; Lipodistrofia Parcial Familiar/genética; Lipodistrofia Parcial Familiar/metabolismo; Lipodistrofia Parcial Familiar/terapia; Metabolismo de los Lípidos/genética; Tejido Adiposo/metabolismo; Tejido Adiposo/patología; Resistencia a la Insulina/genética; Edición Génica

Palabras clave

Hutchinson-Gilford progeria syndrome (HGPS); adipose tissue; aging; familial partial lipodystrophy (FPLD); lamin A; lipodystrophy; mandibuloacral dysplasia (MAD); metabolic syndrome

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Lamina Tipo A / Lipodistrofia Límite: Animals / Humans Idioma: En Revista: Int J Mol Sci Año: 2024 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google